Advanced search

Vol 75, Supp. II (2017)
Commentary
Published online: 2017-03-30

open access

View PDF (Polish) Download PDF file
Page views 296
Article views/downloads 1064
Get Citation

Connect on Social Media

Connect on Social Media

Pierwszy i jedyny preparat złożony beta-adrenolityku oraz inhibitora konwertazy angiotensyny w Polsce — po co? dla kogo? jakie ma główne zalety? jaką ma przyszłość?

Krzysztof J. Filipiak
DOI: 10.5603/KP.2017.0047

Abstract

Not available

Article available in PDF format

View PDF (Polish) Download PDF file

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note